Not provided
Not provided
Not provided
Not provided
Not provided
Recruitment barriers
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Mount Sinai Hospital, Canada | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with recurrent or metastatic sarcoma will be consented to develop a patient derived xenograft (PDX or TumorGraft) model of their tumor to perform drug sensitivity testing. The purpose of the study is to evaluate the accuracy of the patient derived xenograft (PDX) model in predicting patient clinical response to the same drug treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PDX drug sensitivity testing | Other | Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PDX drug sensitivity testing | Other | Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients' whose personalized PDX model accurately predicts clinical response to therapy with same drug treatment. | Overall accuracy as assessed by evaluating Response Evaluation Criteria In Solid Tumors (RECIST) criteria in patient tumor and correlating to tumor regression in PDX model for same drug treatment. | 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients' whose personalized PDX model accurately predicts clinical response to therapy over subsequent lines of therapy. | Overall accuracy as assessed by evaluating RECIST criteria in patient and correlating to tumor regression in PDX model for same drug treatment, over subsequent lines of therapy. | 3 years |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Albiruni Razak, MD | Mount Sinai Hospital, Toronto, Ontario, Canada | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mount Sinai Hospital | Toronto | Ontario | M5G 1X5 | Canada |
Not provided
| ID | Term |
|---|---|
| D012509 | Sarcoma |
| ID | Term |
|---|---|
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Factors that impact on engraftment success. |
% engraftment of tumor as a function of patient and tumor characteristics. |
| 2 years |
| Factors that impact time to drug sensitivity testing. | Time to PDX drug sensitivity testing as a function of patient and tumor characteristics. | 2 years |